首页> 外文期刊>Strahlentherapie und Onkologie >A novel surface imaging system for patient positioning and surveillance during radiotherapy: A phantom study and clinical evaluation
【24h】

A novel surface imaging system for patient positioning and surveillance during radiotherapy: A phantom study and clinical evaluation

机译:用于放射治疗期间患者定位和监视的新型表面成像系统:体模研究和临床评估

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The use of optical surface positioning to support or replace X-ray-based image-guided radiotherapy (IGRT) may reduce patient exposure to extra dose. In specifically designed phantom tests, we analyzed the potential of a new scanning device preclinically. The system's clinical performance was evaluated in comparison to cone-beam computed tomography (CBCT) in a prospective study. Materials and methods: We first evaluated the scanning performance in terms of accuracy and reproducibility using phantom tests. An institutional review board (IRB)-approved clinical evaluation encompassing 224 fractions in 13 patients treated in three different regions (head and neck, thorax, pelvis) was then performed. Patients were first positioned using CBCT and then scanned with the CatalystTM (C-RAD, Uppsala, Sweden) optical system to define the resulting difference vector. Results: Individual system settings are necessary for different scanning conditions. Reproducibility tests with phantoms showed a mean difference of 0.25 ± 0.21 cm. Accuracy tests showed a mean difference of less than 0.52 ± 0.41 cm. Considering all patients, clinical data showed residual target position differences between Catalyst TM (surface-driven) and CBCT (target-driven) systems within 0.07 ± 0.28 cm/- 0.13 ± 0.40 cm/0.15 ± 0.36 cm/0.11 ± 1.57 /- 0.43 ± 1.68/- 0.10 ± 1.67 (lateral/longitudinal/vertical/ rotation/roll/pitch). Conclusion: Scanning quality depends on the color and shape of the scanned surface. Upon prospective clinical evaluation, excellent agreement between target- and contour driven positioning was observed. CatalystTM may reduce CBCT scan frequency in patients where tumor location is fixed relative to the surface.
机译:背景:使用光学表面定位来支持或替代基于X射线的图像引导放射治疗(IGRT)可以减少患者暴露于额外剂量下的风险。在专门设计的幻像测试中,我们在临床前分析了新型扫描设备的潜力。在一项前瞻性研究中,与锥束计算机断层扫描(CBCT)相比,评估了该系统的临床性能。材料和方法:我们首先使用幻像测试评估了扫描性能的准确性和可重复性。然后进行了机构审查委员会(IRB)批准的临床评估,涵盖在三个不同区域(头颈部,胸部,骨盆)治疗的13例患者中的224个分数。首先使用CBCT对患者进行定位,然后使用CatalystTM(C-RAD,瑞典乌普萨拉)光学系统进行扫描,以定义最终的差异向量。结果:对于不同的扫描条件,必须进行单独的系统设置。幻像的再现性测试显示平均差异为0.25±0.21 cm。准确性测试显示,平均差异小于0.52±0.41 cm。考虑到所有患者,临床数据显示Catalyst TM(表面驱动)和CBCT(目标驱动)系统之间的残留目标位置差异在0.07±0.28 cm /-0.13±0.40 cm / 0.15±0.36 cm / 0.11±1.57 /-0.43之内±1.68 /-0.10±1.67(横向/纵向/垂直/旋转/滚动/俯仰)。结论:扫描质量取决于扫描表面的颜色和形状。根据前瞻性临床评估,观察到目标和轮廓驱动定位之间的极佳一致性。对于肿瘤相对于表面固定的患者,CatalystTM可以降低CBCT扫描频率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号